CKD-702 Plus Irinotecan in Gastric Cancer

National Cancer Center (NCC)

Status and phase: Enrolling; Phase 2

Conditions: Gastric Cancer

Treatments: Drug: CKD-702 in combination with irinotecan

Study type: Interventional

Funder types: Other

Identifiers

NCT05750290

100945

Details and patient eligibility

About

CKD-702 is a tetravalent bispecific IgG1 targeting hepatocyte growth factor receptor (MET) and epidermal growth factor receptor (EGFR). The investigators will test a hypothesis that CKD-702 may augment the efficacy of biweekly irinotecan as a 3L or later therapy for gastric cancer overexpressing either MET or EGFR.

Enrollment: 40 estimated patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Failed 2 or more lines of chemotherapy
• Tumor overexpressing either MET or EGFR
• Measurable lesion

Exclusion criteria

• Prior treatment with anti-MET/EGFR bispecific antibody

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

40 participants in 1 patient group

CKD-702 in combination with irinotecan

Experimental group

Treatment:

Drug: CKD-702 in combination with irinotecan